{
  "uuid" : "",
  "id" : "Hormone_therapy_for_prostate_cancer.v0.0.1",
  "gdl_version" : "2.1",
  "concept" : "gt0001",
  "language" : {
    "original_language" : "ISO_639-1::en"
  },
  "description" : {
    "original_author" : {
      "name" : "Kevin Arjona",
      "email" : "kevin.arjona@cambio.se",
      "organisation" : "Cambio CDS",
      "date" : "2025-12-15"
    },
    "lifecycle_state" : "DRAFTED",
    "details" : {
      "en" : {
        "id" : "en",
        "purpose" : "To determine the indication  of hormone therapy based on risk group and endocrine treatment.",
        "keywords" : [
          "prostate",
          "cancer",
          "radiation",
          "therapy",
          "radiotherapy",
          "risk",
          "gnrh",
          "anti-androgen",
          "hormone",
          "adt"
        ],
        "use" : "Use in patients with protate cancer to assess the hormone therapy recommendations.",
        "misuse" : "Not to be used for hormone therapy recommendations in other types of cancer.",
        "copyright" : "© Cambio CDS"
      }
    },
    "other_details" : {
      "references" : "Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16. Erratum in: Lancet. 2009 Apr 4;373(9670):1174. PMID: 19091394.\n\nMottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol. 2012 Aug;62(2):213-9. doi: 10.1016/j.eururo.2012.03.053. Epub 2012 Apr 3. PMID: 22502942.\n\nDenham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011 May;12(5):451-9. doi: 10.1016/S1470-2045(11)70063-8. PMID: 21440505.\n\nNationellt vårdprogram prostatacancer [Internet]. Regionala cancercentrum i samverkan; 2023 [cited 2025 Nov 24]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/",
      "en" : "Recommendations for hormone therapy (ADT)  for prostate cancer."
    }
  },
  "definition" : {
    "data_bindings" : {
      "gt0002" : {
        "id" : "gt0002",
        "model_id" : "openEHR-EHR-OBSERVATION.hormone_therapy_for_prostate_cancer.v0",
        "template_id" : "openEHR-EHR-OBSERVATION.hormone_therapy_for_prostate_cancer.v0",
        "type" : "INPUT",
        "elements" : {
          "gt0003" : {
            "id" : "gt0003",
            "path" : "/data[at0001]/events[at0002]/data[at0003]/items[at0006]",
            "data_type" : "DV_CODED_TEXT",
            "allowed_values" : [
              "local::at0007",
              "local::at0008",
              "local::at0009",
              "local::at0010",
              "local::at0011",
              "local::at0012",
              "local::at0013",
              "local::at0014"
            ]
          },
          "gt0004" : {
            "id" : "gt0004",
            "path" : "/data[at0001]/events[at0002]/data[at0003]/items[at0015]",
            "data_type" : "DV_CODED_TEXT",
            "allowed_values" : [
              "local::at0016",
              "local::at0017",
              "local::at0018",
              "local::at0019",
              "local::at0020"
            ]
          }
        }
      },
      "gt0005" : {
        "id" : "gt0005",
        "model_id" : "openEHR-EHR-EVALUATION.hormone_therapy_for_prostate_cancer_assessment.v0",
        "template_id" : "openEHR-EHR-EVALUATION.hormone_therapy_for_prostate_cancer_assessment.v0",
        "type" : "OUTPUT",
        "elements" : {
          "gt0006" : {
            "id" : "gt0006",
            "path" : "/data[at0003]/items[at0004]",
            "data_type" : "DV_CODED_TEXT"
          },
          "gt0007" : {
            "id" : "gt0007",
            "path" : "/data[at0003]/items[at0010]",
            "data_type" : "DV_CODED_TEXT"
          }
        }
      }
    },
    "pre_conditions" : [
      "$gt0003|Risk Category|!=null",
      "$gt0004|Endocrine treatment during radiation therapy|!=null"
    ],
    "default_actions" : [
      "$gt0006|Recommendation status|=local::at0007|Not recommended|"
    ],
    "rules" : {
      "gt0008" : {
        "id" : "gt0008",
        "priority" : 8,
        "when" : [
          "$gt0003|Risk Category|==local::at0009|Unfavorable intermediate risk|",
          "$gt0004|Endocrine treatment during radiation therapy|==local::at0016|6 months of adjuvant TAB|"
        ],
        "then" : [
          "$gt0006|Recommendation status|=local::at0006|Recommended|"
        ]
      },
      "gt0012" : {
        "id" : "gt0012",
        "priority" : 7,
        "when" : [
          "$gt0003|Risk Category|==local::at0010|High risk|",
          "$gt0004|Endocrine treatment during radiation therapy|==local::at0016|6 months of adjuvant TAB|"
        ],
        "then" : [
          "$gt0006|Recommendation status|=local::at0008|Consider/Conditional|",
          "$gt0007|Comment|=local::at0011|Treatment with bicalutamide or GnRH agonist should continue for 2–3 years after radiotherapy|"
        ]
      },
      "gt0009" : {
        "id" : "gt0009",
        "priority" : 6,
        "when" : [
          "$gt0003|Risk Category|==local::at0010|High risk|||$gt0003|Risk Category|==local::at0011|Very high risk|",
          "$gt0004|Endocrine treatment during radiation therapy|==local::at0017|6 months of TAB followed by adjuvant bicalutamide for 18-36 months|"
        ],
        "then" : [
          "$gt0006|Recommendation status|=local::at0006|Recommended|"
        ]
      },
      "gt0010" : {
        "id" : "gt0010",
        "priority" : 5,
        "when" : [
          "$gt0003|Risk Category|==local::at0012|Very high risk / N1|",
          "$gt0004|Endocrine treatment during radiation therapy|==local::at0018|(24)-36 months of castration + 24 months of abiraterone|"
        ],
        "then" : [
          "$gt0006|Recommendation status|=local::at0006|Recommended|"
        ]
      },
      "gt0011" : {
        "id" : "gt0011",
        "priority" : 4,
        "when" : [
          "$gt0003|Risk Category|==local::at0013|M1 (Low volume)|",
          "$gt0004|Endocrine treatment during radiation therapy|==local::at0019|Castration until further notice + new endocrine preparations|"
        ],
        "then" : [
          "$gt0006|Recommendation status|=local::at0006|Recommended|"
        ]
      },
      "gt0014" : {
        "id" : "gt0014",
        "priority" : 3,
        "when" : [
          "$gt0003|Risk Category|==local::at0014|Postoperative radiation therapy (salvage)|",
          "$gt0004|Endocrine treatment during radiation therapy|==local::at0017|6 months of TAB followed by adjuvant bicalutamide for 18-36 months|"
        ],
        "then" : [
          "$gt0006|Recommendation status|=local::at0006|Recommended|"
        ]
      },
      "gt0013" : {
        "id" : "gt0013",
        "priority" : 2,
        "when" : [
          "$gt0003|Risk Category|==local::at0014|Postoperative radiation therapy (salvage)|",
          "$gt0004|Endocrine treatment during radiation therapy|==local::at0016|6 months of adjuvant TAB|"
        ],
        "then" : [
          "$gt0006|Recommendation status|=local::at0008|Consider/Conditional|",
          "$gt0007|Comment|=local::at0012|In case the pelvic lymph nodes are to be treated and PSA < 0.7 µg/l (If PSA > 0.7, 2 years of bicalutamide is recommended)|"
        ]
      },
      "gt0015" : {
        "id" : "gt0015",
        "priority" : 1,
        "when" : [
          "$gt0003|Risk Category|==local::at0014|Postoperative radiation therapy (salvage)|",
          "$gt0004|Endocrine treatment during radiation therapy|==local::at0020|Adjuvant bicalutamide for 24 months|"
        ],
        "then" : [
          "$gt0006|Recommendation status|=local::at0008|Consider/Conditional|",
          "$gt0007|Comment|=local::at0013|In selected cases in patients who are willing to accept the side effects or who cannot tolerate bicalutamide|"
        ]
      }
    }
  },
  "ontology" : {
    "term_definitions" : {
      "en" : {
        "id" : "en",
        "terms" : {
          "gt0001" : {
            "id" : "gt0001",
            "text" : "Hormone therapy for prostate cancer",
            "description" : "Recommendations for hormone therapy (ADT)  for prostate cancer."
          },
          "gt0002" : {
            "id" : "gt0002",
            "text" : "openEHR-EHR-OBSERVATION.hormone_therapy_for_prostate_cancer.v0"
          },
          "gt0003" : {
            "id" : "gt0003",
            "text" : "Risk Category"
          },
          "gt0004" : {
            "id" : "gt0004",
            "text" : "Endocrine treatment during radiation therapy"
          },
          "gt0005" : {
            "id" : "gt0005",
            "text" : "openEHR-EHR-EVALUATION.hormone_therapy_for_prostate_cancer_assessment.v0"
          },
          "gt0006" : {
            "id" : "gt0006",
            "text" : "Recommendation status"
          },
          "gt0007" : {
            "id" : "gt0007",
            "text" : "Comment"
          },
          "gt0008" : {
            "id" : "gt0008",
            "text" : "Set to recommended case 1",
            "description" : " Unfavorable intermediate risk for 6 months of adjuvant TAB"
          },
          "gt0009" : {
            "id" : "gt0009",
            "text" : "Set to recommended case 2",
            "description" : "High risk or very high risk for 6 months of adjuvant TAB + 2 years "
          },
          "gt0010" : {
            "id" : "gt0010",
            "text" : "Set to recommended case 3",
            "description" : "Very high risk / N1 for 24-36 months castration + 24 months ab"
          },
          "gt0011" : {
            "id" : "gt0011",
            "text" : "Set to recommended case 4",
            "description" : "M1 (lv) for castration + endocrine"
          },
          "gt0012" : {
            "id" : "gt0012",
            "text" : "Set to conditional case 1",
            "description" : "High risk for 6 months of adjuvant TAB"
          },
          "gt0013" : {
            "id" : "gt0013",
            "text" : "Set to conditional case 2",
            "description" : "salvage PRT for 6 months of adjuvant TAB"
          },
          "gt0014" : {
            "id" : "gt0014",
            "text" : "Set to recommended case 5",
            "description" : "salvage PRT for 6 months of adjuvant TAB + 2 years "
          },
          "gt0015" : {
            "id" : "gt0015",
            "text" : "Set to conditional case 3",
            "description" : "salvage PRT for adjuvant bicalutamide"
          }
        }
      }
    }
  }
}